CIK 0002007919 · <br>Emerging growth company
Inhibrx Biosciences, Inc.
Sign in to watch- Ticker
- INBX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 990613523
- Phone
- (858) 795-4220
- Business address
- 11025 N. TORREY PINES ROAD, SUITE 140, LA JOLLA, CA, 92037
- 4 Open-market buy Director bought 6,667 shares at $15.00 ($100,005)
- 4 Open-market buy Chief Executive Officer bought 40,000 shares at an average $15.73 ($629,117)
- 4 Open-market buy Director bought 6,636 shares at an average $15.07 ($99,992)
- 4 Open-market buy Chief Executive Officer bought 44,000 shares at an average $15.25 ($671,150)
- 4 Open-market buy Chief Executive Officer bought 40,000 shares at an average $14.92 ($596,763)
- 4 Open-market buy Director bought 7,140 shares at $14.00 ($99,960)
- 4 Open-market buy Director bought 10,000 shares at $13.98 ($139,800)
- 4 Open-market buy Director bought 75,000 shares at an average $13.83 ($1,037,328)
- 4 Open-market buy Chief Executive Officer bought 40,000 shares at an average $12.96 ($518,282)
- 424B3 Offering Prospectus
- 424B3 Offering Prospectus
- 8-K Event Results of operations · Regulation FD disclosure
- 10-Q Report Quarterly Report
- 4 Gift Director gave 89,050 shares (gift)
- EFFECT Other Notice of Effectiveness
- 424B3 Offering Prospectus
- 8-K Event Regulation FD disclosure
- CORRESP Other Correspondence Between Filers and SEC Staff
- UPLOAD Other SEC-generated Letter
- S-1 Offering Registration Statement
Page 6 of 8 · 158 filings